Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)

Fig. 2

Scoring of value contribution of selexipag to PAH treatment compared to iloprost according to the adapted MCDA framework quantitative criteria. Mean (SD) scores assigned to each quantitative criterion by experts are shown. Error bars show standard deviations across the 28 study participants. A constructed, cardinal scoring scale was used, ranging from 0 to 5 for non-comparative and from − 5 to 5 for comparative criteria, respectively

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172